Synox Therapeutics Secures $75m For Phase 3 Tgct Treatment Trial

By Author: Orson Amiri
Total Articles: 397
Comment this article

SynOx Therapeutics Limited recently closed a $75 million Series B financing, co-led by Forbion, HealthCap, and Bioqube Ventures. This funding will primarily fuel Phase 3 clinical and CMC data generation for emactuzumab, their promising CSF-1(R) inhibiting monoclonal antibody, aimed at treating Tenosynovial Giant Cell Tumour (TGCT). TGCT, a debilitating soft tissue tumour affecting joints and tendons, severely impacts patients' quality of life, often requiring surgical intervention with high recurrence rates.

Emactuzumab, a next-generation CSF-1R mAb, exhibited significant clinical activity in earlier TGCT studies, boasting a 71% objective response rate (ORR) with manageable safety profiles. The company is embarking on a Phase 3 trial (TANGENT) to further evaluate its efficacy and safety. With seasoned additions to the Board of Directors and enthusiastic investor support, SynOx aims to propel emactuzumab towards regulatory approval, potentially addressing a critical unmet need in TGCT treatment.

Read More - https://www.techdogs.com/tech-news/pr-newswire/synox-therapeutics-announces-75m-series-b-round-to-fund-phase-3-trial-of-potential-best-in-class-treatment-for-tgct